Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07731919) titled 'Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis' on July 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
Primary Sponsor: Vast Therapeutics
Condition:
Bronchiectasis Adult
Intervention:
Drug: ALX1
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2026
Target Sample Size: 28
To know more, visit https://clinicaltrials.gov/study/NCT07731919
Disclaimer: Curated by HT Syndication....